FECAL METRONIDAZOLE CONCENTRATIONS DURING ORAL AND INTRAVENOUS THERAPY FOR ANTIBIOTIC ASSOCIATED COLITIS DUE TO CLOSTRIDIUM-DIFFICILE
FECAL METRONIDAZOLE CONCENTRATIONS DURING ORAL AND INTRAVENOUS THERAPY FOR ANTIBIOTIC ASSOCIATED COLITIS DUE TO CLOSTRIDIUM-DIFFICILE
复制标题
DOI：
10.1136/gut.27.10.1169
复制
发表时间：
1986-10-01
期刊：
影响因子：
24.5
通讯作者：
CULSHAW, MA
中科院分区：
文献类型：
--
作者：
BOLTON, RP;CULSHAW, MA
粪便甲硝唑和羟甲硝唑浓度测定高压液相色谱法报告期间艰难梭菌结肠炎的9例患者10次发作。在所有接受口服或静脉注射甲硝唑的急性疾病患者中均存在杀菌粪便浓度，并且均对治疗有反应。甲硝唑和羟基甲硝唑浓度下降，腹泻改善，既不是物质中检测到的5名患者的粪便恢复后。甲硝唑结肠内治疗浓度的证明支持口服甲硝唑有效治疗由C. difficile，也表明静脉注射甲硝唑在这种疾病中的潜在作用。
Faecal metronidazole and hydroxymetronidazole concentrations measured by high pressure liquid chromatography are reported during 10 episodes of Clostridium difficile colitis in nine patients. Bactericidal faecal concentrations were present in all patients with acute disease receiving oral or intravenous metronidazole, and all responded to therapy. Metronidazole and hydroxymetronidazole concentrations fell as the diarrhoea improved and neither substance was detectable in the faeces of five patients after recovery. This demonstration of intracolonic therapeutic concentrations of metronidazole supports the clinical experience of oral metronidazole being effective in the treatment of antibiotic associated diarrhoea caused by C. difficile and also suggests a potential role for intravenous metronidazole in this disease.